Pharmaceutical - Markets & Marketing, Gastro-intestinals

Filter

Popular Filters

1 to 25 of 36 results

Takelda combination tablets now available in Japan

Takelda combination tablets now available in Japan

13-06-2014

Japan’s largest drugmaker Takeda Pharmaceutical says that Takelda, a fixed-dose combination (FDC) of…

Gastro-intestinalsJapanMarkets & MarketingPharmaceuticalTakeda PharmaceuticalTakelda

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

Approval of Takeda’s Entyvio marks “historic change” for IBD treatment

03-06-2014

The recent approval of Japanese drug major Takeda’s Entyvio (vedolizumab) by the European Medicines…

EntyvioGastro-intestinalsHumiraMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionStelaraTakeda Pharmaceutical

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

Astellas and UMN update on Ph III trials of flu vaccine ASP7374; debuts Irribow OD in Japan

15-01-2014

Japanese drug major Astellas Pharma and partner UMN Pharma have announced promising summary results for…

Asia-PacificASP7374Astellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceuticalResearchUMN PharmaVaccines

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

Ipsen prepares for EU resupply of Increlex; enters deal with Mayoly Spindler

18-12-2013

French drugmaker Ipsen says that Lonza has successfully re-manufactured the active ingredient of Increlex…

Anti-Arthritics/RheumaticsEuropeGastro-intestinalsIncrelexIpsenLonzaMarkets & MarketingMayoly SpindlerPharmaceuticalProductionRare diseases

NovaMedica to distribute Aptalis products in Russia

06-12-2013

Russian drugmaker NovaMedica, a joint enterprise between the Russian high-technology investment fund…

Aptalis PharmaEastern EuropeGastro-intestinalsLicensingMarkets & MarketingNovaMedicaPharmaceuticalRussia

Opioid-induced constipation market expected to see rapid growth by 2017

Opioid-induced constipation market expected to see rapid growth by 2017

13-10-2013

The global market for opioid-induced constipation will increase significantly from $144.42 million in…

AstraZenecabevenopranCubist PharmaceuticalsEuropeGastro-intestinalsMarkets & MarketingnaloxegolNorth AmericaPharmaceuticalRelistorSalix Pharmaceuticals

AstraZeneca’s naloxegol marketing application accepted by EMA

AstraZeneca’s naloxegol marketing application accepted by EMA

27-09-2013

The European Medicines Agency has accepted AstraZeneca’s Marketing Authorization Application for naloxegol…

AstraZenecaEuropeGastro-intestinalsMarkets & MarketingnaloxegolNektar TherapeuticsPharmaceuticalRegulation

Astellas gains marketing approval for Irribow

16-08-2013

Japanese drug major Astellas Pharma (TYO: 4503) has gained marketing approval in Japan for Irribow (ramosetron…

Asia-PacificAstellas PharmaGastro-intestinalsIrribowMarkets & MarketingPharmaceutical

$10 million milestone for Sucampo, as Takeda starts US selling of Amitiza for OIC

27-06-2013

USA-based Sucampo Pharmaceuticals (Nasdaq: SCMP) says that it has received a $10 million milestone payment…

AmitizaFinancialGastro-intestinalsMarkets & MarketingNorth AmericaPharmaceuticalSucampoTakeda Pharmaceuticals

First approved new class of IBS-C therapy, Constella, now available in Europe

13-06-2013

Spain's largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD)…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsMarkets & MarketingPharmaceuticalRegulation

Vedolizumab has potential to offer improvement over infliximab in UC

30-04-2013

Surveyed US and EU5 gastroenterologists agree that new moderate to severe ulcerative colitis (UC) therapies…

EuropeGastro-intestinalsinfliximabJanssenMarkets & MarketingMerck & CoNorth AmericaPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

US gastroenterologists increasingly using biologics to treat Crohn's patients in remission

06-03-2013

Although there have been no significant changes with regard to biologic treatment and Crohn's disease…

AbbVieBiotechnologyCimziaGastro-intestinalsHumiraJanssenMarkets & MarketingNorth AmericaPharmaceuticalRemicadeUCB

Astellas starts European roll-out of OAB drug Betmiga in UK

27-02-2013

The European subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) has started the European launch…

Astellas PharmaBetmigaEuropeGastro-intestinalsMarkets & MarketingPharmaceutical

News briefs: Lexicon's IBS drug; Sanofi Pasteur launch in Thailand; Tranzyme drops TZP-102

17-12-2012

US drug developer Lexicon Pharmaceuticals (Nasdaq: LXRX) saw its shares leap 9.1% to $2.04 in premarket…

DiabetesGastro-intestinalsLexicon PharmaceuticalsLX1033Markets & MarketingPharmaceuticalRegulationResearchSanofiSanofi PasteurTranzymeTZP-102Vaccines

Abbott launches Sucampo's Amitiza in Japan

27-11-2012

US drugmaker Sucampo Pharmaceuticals (Nasdaq: SCMP), and marketing partner health care major Abbott Laboratories…

Abbott LaboratoriesAmitizaAsia-PacificGastro-intestinalsMarkets & MarketingPharmaceuticalSucampo

Researchers bust a gut to improve gastrointestinal disorders market

28-10-2012

Drugs to treat gastrointestinal disorders are due to see a significant price drop, as patents run out…

Gastro-intestinalsGenericsMarkets & MarketingPharmaceutical

AstraZeneca gains rights to sell Ironwood's IBS drug in China

24-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

1 to 25 of 36 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top